Lead Immunothrombosis Researcher & Educator

Immunothrombosis, or the interaction between immune responses and coagulation, contributes to cardiovascular disease by promoting microvascular thrombosis, inflammation, and endothelial dysfunction. Despite the widespread use of antiplatelet drugs, which target only some of the mechanisms involved, this process continues to affect patients, revealing the limitations of current therapies. Infections significantly increase the risk and severity of cardiovascular disease, probably by enhancing immunothrombosis, although the exact mechanisms remain unclear. The main objective is to identify the mediators that drive this immunothrombotic cascade among the cellular and molecular actors of haemostasis. The long-term goal is to develop strategies capable of targeting certain elements, for example via nanobodies, to neutralize inflammation‑induced thrombosis while preserving haemostasis.

The teaching project will focus on haemostasis, vascular pathophysiology, and immunothrombosis in several master's programs at Paris‑Saclay University and Paris‑Cité University. The candidate will organize and participate in teaching units on immunohematology within the Master's 1 and Master's 2 international programs in "Drug and Health Product Development (D2HP, D. Bonte and S. Tfaili), which is taught in English, teaching units on haemostasis within the Master 2 program in Biology for Innovative Therapies and Diagnostics (BioInnov, G. Schlecht Louf and N. Chaput), and the Master 2 program in Cardiovascular Sciences (M2SC, D. Faille, G. Caligiuri, and JS. Silvestre). The candidate will also supervise practical sessions on communication in research within the Master 2 program in Pharmaceutical Biotechnology and Innovative Therapies (BPTI, C. Smadja and I Turbica).